Cell Therapeutics presses on with EU plans for pixantrone in NHL
This article was originally published in Scrip
Executive Summary
Cell Therapeutics is continuing with its plans to file pixantrone in the EU for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL), despite the US FDA turning down its lead drug candidate in April for the same indication.